UPDATE: Citi Downgrades Celgene (CELG) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Celgene (CELG) PT Lowered to $145 at Credit Suisse, Remains Focus List Stock
October 20, 2017 8:01 AM EDTCredit Suisse lowered its price target on Celgene (NASDAQ: CELG) to $145.00 (from $156.00) while maintaining a Outperform rating.
Analyst Alethia Younf comments "We are lowering our probability of success from 75% to 20% for our Crohns franchise revenues but keep some revenues in since the company... More
Celgene (CELG) PT Lowered to $154 at Canaccord Genuity
October 20, 2017 5:53 AM EDTCanaccord Genuity lowered its price target on Celgene (NASDAQ: CELG) to $154.00 (from $156.00) while maintaining a Buy rating.
Analyst John Newman lowers his PT following the late Thursday announcement that the company has discontinued Phase 3 REVOLVE trial and SUSTAIN extension trial. The analyst... More
Baird Downgrades Celgene (CELG) to Neutral
October 20, 2017 2:13 AM EDTBaird downgraded Celgene (NASDAQ: CELG) from Outperform to Neutral with a price target of $136.00 (from $162.00).
Analyst Brian Skorney cites the GED-0301 failure for the incrementally more negative view on the company noting IP concerns are now coming into focus commenting "this failure comes at a time... More
Celgene (CELG) to Stop GED-0301 Phase III REVOLVE Trial Following Interim Futility Analysis
October 19, 2017 4:32 PM EDTCelgene Corporation (NASDAQ: CELG) today announced that the GED-0301 (mongersen) phase III REVOLVE trial (CD-002) in Crohns disease (CD) and the extension trial (SUSTAIN, CD-004) will discontinue. Celgene has decided to stop the trials following an October recommendation of the Data Monitoring Committee,... More
